Skip to main content
Clinical Trials/CTRI/2018/06/014579
CTRI/2018/06/014579
Recruiting
Phase 4

An Observational, prospective, comparative study of the effectiveness and safety of Liposomal Amphotericin-B versus Miltefosine in the treatment of Post Kala-Azar Dermal Leishmaniasis (PKDL).

Department of Pharmacology0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Suffering from Post Kala Azar Dermal Leishmaniasis
Sponsor
Department of Pharmacology
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\)A clinical diagnosis of active PKDL with characteristic skin lesion.
  • 2\)Confirmed diagnosis with biopsy of the skin (lesional segment) lesion.
  • 3\)Male or female of age 18\-65 yrs.

Exclusion Criteria

  • 1\)Pregnant or lactating women
  • 2\)Refusal to use contraceptives during the treatment period and 2 months after completion of treatment with miltefosine
  • 3\) HIV positive serology.
  • 4\)Patients with co\-morbid liver, kidney diseases
  • 5\)Anaphylactic reaction with Amphotericin B

Outcomes

Primary Outcomes

Not specified

Similar Trials